A Novel Druglike Spleen Tyrosine Kinase Binder Prevents Anaphylactic Shock when Administered Orally

BACKGROUND: The spleen tyrosine kinase (Syk) is recognized as a potential pharmaceutical target for the treatment of type I hypersensitivity reactions including allergic rhinitis, urticaria, asthma, and anaphylaxis because of its critical position upstream of immunoreceptor signaling complexes that regulate inflammatory responses in leukocytes. OBJECTIVE: Our aim was to improve the selectivity of anti-Syk therapies … Continued

1 of 1
Back to top
Powered by Translations.com GlobalLink OneLink Software